A Pill, Not a Shot: FDA Clears Merck’s First Oral PCSK9 Inhibitor

On a quiet Thursday afternoon in July 2026, the U.S. Food and Drug Administration announced the approval of a drug that has been whispered about in cardiology circles for a while now: Lipfendra, whose generic name is enlicitide. It’s not just another statin; it belongs to the PCSK9 inhibitor family – but unlike its injectable cousins, Lipfendra comes in a tiny tablet you can swallow with water.

Merck, the pharmaceutical giant behind the pill, says this is the first oral PCSK9 inhibitor that has ever hit the market. The company’s executive vice president, Brian Foard, summed it up in plain language: "Seventy percent of patients on existing therapies still miss guideline‑recommended LDL goals. That’s a huge gap, and oral Lipfendra could help close it." The quote may sound like marketing copy, but the numbers behind it are striking.

In two late‑stage clinical trials, participants with hypercholesterolemia saw, on average, about a 60% reduction in their low‑density lipoprotein (LDL) cholesterol levels. To put that into perspective, most statins manage a 30‑40% drop, and the injectable PCSK9 drugs that preceded Lipfendra hover around the same 60% mark – but they require a needle every two weeks or month. For patients who dread shots or struggle with regular clinic visits, a once‑daily pill could be a game‑changer.

The FDA’s decision came after a review of the trial data, which, according to the article, did not raise any new safety flags. In fact, the developers highlighted that no allergy risks – a concern that sometimes surfaces with injectable biologics – were observed in the large study populations. Still, the public record does not name the specific trial identifiers or provide a peer‑reviewed publication, so clinicians will likely wait for those details before fully embracing the new option.

Why does this matter? Roughly a quarter of the 200 million Americans with elevated cholesterol fall into the “hypercholesterolemia” bucket – a group that includes people with genetic conditions like familial hypercholesterolemia. Those patients, and many others with high cardiovascular risk, often remain undertreated. An analyst at RBC Capital Markets, Trung Huynh, pointed out that over 70% of eligible high‑risk atherosclerotic cardiovascular disease patients are not hitting their LDL targets, largely because of injection aversion and other access hurdles.

Merck’s press release, quoted in the article, frames Lipfendra as a bridge between traditional statins and the newer injectable biologics. If the pill lives up to its promise, doctors may finally have a middle‑ground therapy that’s both potent and convenient.

Of course, real‑world use will reveal the true picture. Physicians will want to see long‑term outcome data – does the LDL drop translate into fewer heart attacks and strokes? And patients will be watching the price tag, as PCSK9 inhibitors have historically carried a steep cost.

For now, the approval marks a notable milestone in cholesterol management: a pill that could replace a needle for many, and perhaps bring more people within reach of guideline‑recommended LDL levels.